Medical-Device Biological Evaluation: A Risk-Based Evidence Route

Updated2026-07-14

Medical-device biological evaluation route from finished-device and contact inputs to endpoint-by-endpoint evidence decisions — BIO original evidence map. Start with the final device, manufacturing/sterilization and contact; address each endpoint with existing evidence, chemistry/toxicology, targeted testing or a justified rationale; record gaps and residual risk. Not a test checklist. Figure sources [1–5]; endpoint-framework supplement [6].

In short: ISO 10993-1 places medical-device biological safety evaluation within a risk-management process [1–2]. FDA implementation starts with material components, manufacturing and sterilization, anatomical contact, contact type, frequency and duration, and assesses the final finished device rather than a raw material alone [3–4]. Contact categories and endpoint tables identify risks to address; they are not a fixed testing checklist. Each relevant endpoint can be addressed with existing data, endpoint-specific testing, or a scientific rationale for why no further assessment is needed [6].

Step 1: define the final finished device and exposure

FDA assesses the device in its final finished form, including sterilization where applicable, and considers component interactions, material processing, manufacturing methods and manufacturing-aid residuals [3–4]. Supplier material data are inputs, not a substitute finished-device conclusion.

Step 2: identify biological endpoints to address

Nature and type of contact, anatomical site, frequency and duration help identify relevant endpoints. FDA explicitly calls its endpoint tables an evaluation framework rather than a testing checklist; a particular device may need more or fewer endpoints than the tables indicate [6].

Step 3: match evidence to each endpoint

Compile material composition, prior device or material evidence, manufacturing and sterilization information, and assess its relevance to the current device.
ISO 10993-18 chemical characterization can cover construction materials, manufacturing-introduced substances, extractables, leachables and degradation products [5].
ISO 10993-17 covers toxicological risk assessment of medical-device constituents [5].
Use endpoint-specific testing for remaining gaps, or provide a scientific rationale for no further assessment; do not claim that chemistry automatically replaces every biological test [5–6].

Step 4: record conclusions, gaps and residual risk

The report should show how each endpoint was addressed, why evidence applies to the final device, what uncertainty remains, and when design, manufacturing, sterilization or contact changes trigger reassessment. Confirm the recognized ISO edition, national adoption and regulator guidance for the target market and submission date.

Sources and reading limits

ISO 10993-1:2025: general principles for biological safety evaluation within risk management.
ISO 14971:2019: medical-device risk-management framework.
FDA ISO 10993-1 Guidance (2023): FDA implementation context; regulatory recognition must be checked separately from ISO's 2025 edition.
FDA Biocompatibility Basics: final finished device, manufacturing and contact inputs.
ISO 10993-18:2020 chemical characterization and ISO 10993-17:2023 toxicological risk assessment.
FDA Endpoint Framework: not a test checklist; endpoints can be addressed by data, testing or rationale.

The BIO angle

BIO can help assemble available TDS, CoA, compliance statements and lot information for a specific medical-grade silicone grade as evaluation inputs. Availability and scope are product-specific; BIO does not replace the device manufacturer's biological evaluation, test design or regulatory conclusion.

FAQ

Must every test shown in an endpoint table be run?

No. Endpoint tables identify biological risks to address; they are not a fixed test checklist. Each relevant endpoint should be handled with applicable existing evidence, endpoint-specific testing or a sound rationale.

Does biological evaluation assess only raw materials?

No. FDA assesses the final finished device and considers component interactions, manufacturing, sterilization and process residuals. Material information is one evidence input.

Can chemical characterization replace every biological test?

Not automatically. Chemistry and toxicological risk assessment can address specific endpoints; only when relevance and sufficiency are justified might no new endpoint test be needed. Otherwise additional evaluation or testing remains necessary.

How do ISO 10993 and GB/T 16886 relate?

China has adopted substantial ISO 10993 content through the GB/T 16886 series, but current editions, degree of adoption and regulatory references can differ by part and date. Verify the applicable route rather than assuming every edition is permanently one-to-one.

Medical-device biological evaluation: a risk-based evidence route